Clinical Trial Update: Escitalopram to Placebo in Patients With Localized Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 randomized trial comparing escitalopram to placebo in localized pancreatic cancer was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma
• Periampullary Cancer

Drugs mentioned

• Escitalopram (escitalopram)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Pancreatic Ductal Adenocarcinoma, Periampullary Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-12-10